RxDoctor Payments Data

Christianna Bull

Family · Salisbury, MDNPI 1477306603

Payments from drug & device makers

$1,837in general payments, 2019–2025

Across 81 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$246
  • Alkermes, Inc.$195
  • Lundbeck LLC$185
  • Teva Pharmaceuticals USA, Inc.$179
  • Otsuka America Pharmaceutical, Inc.$162
  • Vanda Pharmaceuticals Inc.$152
  • plus $719 from 11 others

What the payments were for

  • Food & beverage$1,837100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,837 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$16,940
Medicare patients
89
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide21$20,754
JardianceEmpagliflozin22$13,339
RybelsusSemaglutide11$10,566
Varenicline Tartrate14$4,688
Albuterol Sulfate HfaAlbuterol Sulfate56$2,024
Atorvastatin Calcium136$1,538
Omeprazole79$957
Fluticasone Propionate55$884
Metformin Hcl103$835
Gabapentin32$670
Oxybutynin Chloride ErOxybutynin Chloride28$663
Levothyroxine Sodium76$656
Amlodipine Besylate87$611
Losartan Potassium56$591
Ondansetron OdtOndansetron28$499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$22$10,56611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →